Annovis Bio stock price jumps on positive news about experimental Alzheimer’s disease therapy

The Berwyn drug developer is conducting a phase 2/3 clinical trial to test its lead drug candidate buntanetap as a treatment for mild to moderate Alzheimer’s disease.

Previous CVS sues US gov't over $400 million tax dispute
Next Harvest Food Group names Amit Pandhi president and CEO